Theriva Biologics
TOVX
26 hedge funds and large institutions have $33.1M invested in Theriva Biologics in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
4% less funds holding
Funds holding: 27 → 26 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
37% less capital invested
Capital invested by funds: $53M → $33.1M (-$19.8M)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$190K |
| 2 |
Bank of New York Mellon
New York
|
+$63.4K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$31.7K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$15.9K |
| 5 |
CCM
Check Capital Management
Costa Mesa,
California
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.14M |
| 2 |
Morgan Stanley
New York
|
-$555K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$476K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$360K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$257K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $13K | +$15.9K | +1 | New |
|
|
U
27
UBS
Zurich,
Switzerland
| $6K | – | – | – |
|
|
GT
28
Glenmede Trust
Philadelphia,
Pennsylvania
| $4K | – | – | – |
|
29
BNP Paribas Financial Markets
Paris,
France
| $1.9K | – | – | – |
|
30
Citigroup
New York
| $1K | – | – | – |
|
|
GSC
31
Ground Swell Capital
Folly Beach,
South Carolina
| $1K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
EI
33
EAM Investors
Solana Beach,
California
| – | -$1.14M | -51 | Closed |
|
|
34
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$360K | -16 | Closed |
|
|
LP
35
LMR Partners
London,
United Kingdom
| – | -$257K | -11 | Closed |
|
|
CS
36
Credit Suisse
Zurich,
Switzerland
| – | -$176K | -8 | Closed |
|
37
Wells Fargo
San Francisco,
California
| – | -$64K | -3 | Closed |
|
38
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | – | – |
|
TOVX Hedge Fund Activity: Q2 2014 in Review
26 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2014, worth a combined $33.1M — down 37% from $53M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TOVX and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 1 added.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $190K. The largest seller was EAM Investors, exiting entirely with an estimated $1.14M sold.
- 26 institutional investors held Theriva Biologics (TOVX) as of Q2 2014, down from 27 in Q1 2014.
- Funds reported $33.1M of Theriva Biologics stock for Q2 2014, down 37% quarter-over-quarter.
- 4 funds opened new Theriva Biologics positions in Q2 2014 and 5 closed out, a net change of -1 holder.
- The largest Theriva Biologics buyer in Q2 2014 was A.R.T. Advisors, an estimated $190K added.
- The largest Theriva Biologics seller in Q2 2014 was EAM Investors, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2014.